{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.14","upperLimit":"12.98","value":"2.69"},{"groupId":"OG001","lowerLimit":"1.28","upperLimit":"15.24","value":"2.96"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"description":"Overall survival is defined as time from first dose to death due to any cause.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants received GSK3326595 400 mg, tablets, orally, once daily until progression, unacceptable toxicity, or withdrawal of consent during Part 1 of the study.","id":"OG000","title":"Part 1: GSK3326595 400 mg"},{"description":"Participants received GSK3326595 300 mg, tablets, orally, once daily until progression, unacceptable toxicity, or withdrawal of consent during Part 1 of the study.","id":"OG001","title":"Part 1: GSK3326595 300 mg"}],"paramType":"MEDIAN","populationDescription":"All Treated Population.","reportingStatus":"POSTED","timeFrame":"Up to 30.8 months","title":"Part 1: Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}